FDA-grade engineering for clinical and commercial systems
Healthcare — Pharmaceuticals & Life Sciences
What the compliance landscape actually demands.
Pharmaceutical technology regulation is among the most demanding in any industry, and the gap between what software teams believe it requires and what FDA inspectors actually examine is substantial. FDA 21 CFR Part 11 governs every electronic system used in the context of FDA regulations — clinical trial management systems, LIMS, manufacturing execution systems, QMS, regulatory submission platforms. Part 11 requires that these systems are validated before use in regulated activities: documented testing demonstrating the system performs its intended function accurately and reproducibly, with audit trails that are computer-generated and tamper-evident, electronic signatures that meet FDA's legal equivalence standard, and access controls with individual accountability. Validation is not a one-time event. It must be maintained through every system change under a formal change control procedure, with documentation demonstrating that each change did not adversely affect the validated state. The EU GMP Annex 11 requirements parallel Part 11 but add specific mandates around cloud infrastructure qualification, backup and recovery testing, and data integrity controls that most cloud service agreements do not automatically satisfy. ICH E6(R3), finalized in 2023, introduced risk-based clinical trial management requirements with significant technology implications — sponsors must use systems supporting centralized statistical monitoring, risk-based monitoring workflows, and electronic patient-reported outcomes that satisfy Part 11.
FDA 21 CFR Part 11 compliance cannot be added to a finished system — validation is an architecture decision, and retrofitting it costs three to five times more than building it right.
Pharmaceutical technology lives under FDA 21 CFR Part 11. Data integrity isn't optional — it's existential. Clinical trial data, manufacturing execution, regulatory submissions — every system requires validated, compliant infrastructure.
Talk to an Engineer →
First call is a senior engineer — not a sales team. We understand your regulatory environment before we write a line of code.
Start a ConversationWhere Incumbents Fall Short
The Part 11 compliance failure mode in pharmaceutical technology is predictable: a software team builds a capable clinical or manufacturing system, the regulatory affairs team identifies Part 11 as a requirement late in the project, and the validation exercise reveals that the architecture does not support the required audit trail, the access control model doesn't satisfy individual accountability requirements, and the electronic signature implementation doesn't meet FDA's definition. Retrofit validation is expensive — typically three to five times the cost of building compliant from the start — and often requires system changes that delay go-live by six to twelve months. In the clinical trial context, delays translate directly to extended development timelines and increased study costs. In manufacturing, delays affect product launch schedules and create gap periods in production documentation that FDA inspectors will scrutinize. The data integrity failures that produce FDA warning letters are almost always architectural — systems that allow record modification without audit trail capture, shared accounts that prevent individual accountability, and time stamp implementations that are not reliable because they depend on client-side clocks.
How We Approach Pharmaceuticals & Life Sciences
The Algorithm designs pharmaceutical systems with validation as the organizing principle of the architecture. The audit trail is not a feature added after the core functionality is built — it is the foundation on which the application logic sits. Every record creation, modification, or deletion event generates a tamper-evident audit entry with the user identity, timestamp, reason for change, and previous value. Access controls are implemented with role-based permissions tied to individual user accounts, with no shared credentials at any system level. Electronic signature workflows satisfy the two-component identification requirement for Part 11 signatories. The validation documentation package — Installation Qualification, Operational Qualification, Performance Qualification, and User Requirements Specification — is produced as a byproduct of the build process, not as a retroactive documentation exercise. GAMP 5 category classification is determined at the architecture phase, and the validation strategy is designed proportionate to the software category. The result is a system that enters the FDA inspection environment with a complete evidence package and a validation state that has been maintained through every change.
What Success Looks Like
A successful engagement delivers validated clinical or manufacturing software with a complete Part 11 evidence package — URS, IQ, OQ, PQ documentation — that satisfies an FDA inspection without a single 483 observation related to electronic records. The audit trail captures every regulated record event with individual accountability. Electronic signatures meet the two-component identification requirement. The system integrates with existing QMS and ERP platforms without creating data integrity gaps at the interface. Change control procedures maintain the validated state through every subsequent modification. The regulatory affairs team can file submissions with confidence that the underlying system documentation will survive agency review. The quality team can close CAPAs without discovering that the system they closed them in doesn't satisfy Part 11.
Duration: 8 - 16 weeks
Output: Production system + audit documentation
A pharmaceutical company building validated clinical data systems typically engages at Tier II — multiple workstreams, FDA audit trail built in.
What We Deploy in Pharmaceuticals & Life Sciences
Healthcare — Pharmaceuticals & Life Sciences Compliance Assessment
A structured checklist for evaluating your AI and software vendor's readiness across the key regulatory frameworks in Healthcare. Free — no email required.
Download PDF →Ready When You Are
Working in Pharmaceuticals & Life Sciences?
We've deployed teams in this environment. First call is a senior engineer.
Engineering Specifics — Healthcare
Audit-trail architecture that captures the named user, the resource accessed, the operation performed, and the workstation identity in a format FDA 21 CFR PART 11 examiners directly accept — not a log file that requires translation for an external audit.
Access-control logic enforced at the data layer rather than the application layer — every read of a regulated record validates authorization against the live scope of the requesting principal, preventing the cross-scope exposure that has produced multiple OCR and FFIEC findings in Healthcare environments.
Encryption configured to the specific cipher-suite and key-management requirements FDA 21 CFR PART 11, HIPAA, SOC 2 actually mandates, not the closest nominal default. Key rotation, key-access logging, and key-escrow architecture are designed at engagement intake, not after the first audit.
Incident-response architecture that satisfies the strictest notification timeline among FDA 21 CFR PART 11, HIPAA, SOC 2. Pre-staged runbooks, pre-drafted regulator-facing templates, and automated detection-to-paging pipelines make the published notification deadlines architecturally enforceable rather than procedurally aspirational.
Continuous compliance evidence generation rather than retroactive assembly — every change-control event, access-provisioning event, and configuration update produces structured records aligned to FDA 21 CFR PART 11 on the day the event happens, queued for the next audit pack with no manual reconstruction.
Quarterly audit pack delivered to your compliance officer without a request — workforce roster, access events, change attribution, incident register, training-currency report, mapped to FDA 21 CFR PART 11, HIPAA, SOC 2 in the format your audit program already uses.
What We Ship — Healthcare
A working production system in your tenancy, FDA 21 CFR PART 11-compliant from commit one, delivered on the named milestone date — not a discovery document, not a refactor backlog, not a phase-two scope-expansion request.
Compliance baseline documentation aligned to FDA 21 CFR PART 11, HIPAA, SOC 2 for Healthcare — workforce attribution logs, data-flow diagrams, access-control inventory, encryption-key inventory, incident-response runbook — delivered as engagement artifacts, not assembled before the first audit.
IP and source-code transfer effective from day one — your engineering team owns the repository, the deployment pipeline, the infrastructure-as-code; we do not hold operational hostage and the cost model rewards us for delivery, not retention.
Knowledge transfer that survives the engagement — every operational decision documented in runbooks an on-call engineer can follow at 3 AM without paging us. The deliverable is autonomy, not dependency.
ALICE compliance enforcement integrated into your CI pipeline before engagement close — FDA 21 CFR PART 11, HIPAA, SOC 2 anti-patterns are blocked before they merge, so the compliance posture does not drift between audit cycles.
Post-engagement retainer optionally available for the first six months — defined escalation path to the original engagement team for incidents or critical questions. Most clients do not need it, because the system is designed to be operated without us.
Common Findings We Remediate — Healthcare
Audit-trail gaps: log records that exist but cannot be joined back to a named user, a specific resource, and a timestamp from a synchronized source. Reconstructed under examination, the gaps show up as "we cannot determine who did this" — the finding regulators specifically write up under FDA 21 CFR PART 11, HIPAA, SOC 2.
Authorization-vs-authentication confusion: code paths that verify the requesting principal is logged in but do not verify the principal is authorized for the specific resource. The result is cross-scope data exposure that has produced OCR, FFIEC, and ICO settlements in Healthcare environments at scale.
Encryption configured to a nominal label rather than the specific cipher-suite, key-length, and key-management requirements FDA 21 CFR PART 11, HIPAA, SOC 2 actually mandates. The audit finding is "encryption is implemented but not validated"; the architecture fix is to pin the implementation to a validated cryptographic module from engagement start.
Incident-response runbooks that exist as documents but have never been exercised against the specific notification timelines Healthcare obligations impose. The first real incident is the wrong time to discover the runbook references a tool no one configured or a contact who no longer works at the organization.
Vendor-management and BAA-equivalent gaps: third-party services that receive regulated data without the contractual basis that FDA 21 CFR PART 11, HIPAA, SOC 2 requires. The pattern is usually accidental — a new SaaS integration added during a sprint without compliance review — and produces a finding under every modern regulatory framework.
Compliance evidence assembled retroactively before the audit cycle, then re-assembled before the next one — burning meaningful margin for engagement work that should be generated continuously by the deployment pipeline. The fix is once: instrument the systems to produce audit evidence as a byproduct of normal operations, not on demand.
Why The Algorithm — Healthcare
The Healthcare engineering market is crowded with generalist firms claiming sector competence and sector specialists with limited engineering depth. The combination — deep engineering capability and operational Healthcare compliance fluency — is rare, and that gap is where the most expensive vendor failures happen.
Our teams come through the Algonauts pipeline trained on FDA 21 CFR PART 11, HIPAA, SOC 2 before they touch a client codebase in Healthcare. The training is not optional and not certificate-only — engineers must demonstrate working competence on representative compliance scenarios before they are deployed. This is the reason our Healthcare clients do not see the "compliance was an afterthought" pattern that drives most remediation engagements.
Engagement pricing is fixed. The price you agree at engagement start is the price at delivery. Scope changes that materially expand the engagement are negotiated transparently as change orders; we do not bury scope creep in velocity reports or sprint backlogs. The economic model rewards us for delivering, not for billing — and that alignment is the foundation under everything else above.
Common Procurement Questions — Healthcare
How is this engagement different from staff augmentation?
Staff augmentation places named contractors against an hourly rate card; the client retains accountability for delivery, methodology, and code quality. Our engagements are fixed-price commitments against named milestones; we retain accountability for delivery and ship the system as a deliverable, not the engineers as a resource. The contractual posture, the team composition, and the economic incentives are different.
What happens if the engagement scope changes?
Material scope expansions are negotiated transparently as change orders against the original engagement. We do not bury scope creep in velocity reports or sprint backlogs. Minor clarifications and emergent design decisions are absorbed without change orders — the fixed-price commitment includes a reasonable allowance for in-scope adjustments that any real engineering project requires.
What does post-delivery support look like?
The deliverable is designed to be operated by your team without our continued involvement. Documentation, runbooks, and the ALICE compliance enforcement layer continue to enforce the standards after we leave. Optional retainer support is available for organizations that want a defined escalation path to the engagement team for the first six months; most clients do not need it.
How do you handle data access during the engagement?
Production data access for our engineers is mediated through the same compliance controls that govern your internal engineering team. Named workforce documentation, framework-specific training currency, background checks, and BAA or equivalent agreements are completed before access provisioning. Access events are logged with the engineer's named identity, not a shared service account.
What is the procurement path?
Most engagements begin with a 30-minute scoping conversation, followed by a written engagement proposal within five business days that specifies scope, milestones, fixed price, and named team members. Standard contracting cycles complete within two weeks of proposal acceptance. We are familiar with enterprise procurement gating (vendor onboarding, SOC 2 review, BAA execution, MSA negotiation) and we support these processes without billable consulting overhead.